Only 1 of 11 Canadian Medical Associations Covers GLP-1 Obesity Drugs, Despite Lower Costs
Updated
Updated · Medscape · Jun 16
Only 1 of 11 Canadian Medical Associations Covers GLP-1 Obesity Drugs, Despite Lower Costs
3 articles · Updated · Medscape · Jun 16
Summary
Only one of 11 Canadian provincial medical associations currently reimburses GLP-1 drugs for obesity in physician health plans; one more reviews claims case by case, and two plan coverage in summer 2026.
Canada’s national medical association plan also excludes the drugs, even though Canadian GLP-1 prices run about $150-$300 a month, or roughly $1,750-$3,500 a year.
Those costs are below a 2025 ICER draft estimate that semaglutide would remain cost-effective at $9,200-$12,600 annually, while obesity is estimated to cost Canada $5.9 billion in direct care and $21.7 billion indirectly.
The report says the main barriers are not novelty or efficacy—semaglutide and tirzepatide deliver average weight loss of 14.9% and 20.9%—but employer concerns over cost, delayed returns, and persistent weight bias.
Coverage remains limited beyond physician plans: a 2025 survey found only 31% of Canadian employers cover GLP-1s for weight loss, though broader insurer adoption is expected within 3-5 years.
With Canada's new generic GLP-1s, how long until insurers stop treating obesity differently than other chronic diseases?
GLP-1s reduce heart attacks and other major health costs, so why is insurance coverage for obesity still so rare?
The Changing Landscape of GLP-1 Coverage for Obesity in Canada: Generics, Insurance Barriers, and Public Health Impact
Overview
As of June 2026, GLP-1 drug coverage for obesity in Canada is expanding, but many people without private insurance still face the tough choice of paying full price or skipping treatment. The arrival of cheaper, generic versions of GLP-1 drugs like Ozempic and Wegovy is a major development, making Canada the first country to offer these affordable options. This change is seen as a huge step, giving more Canadians the chance to manage weight and related health issues at a lower cost. For those with insurance, generics will usually be covered automatically, improving access and reducing financial barriers.